Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Getting More Money Up Front Under Cures Bill Revisions

Dec 01 2016

• By Derrick Gingery

FDA entrance sign 2016

Related Content

FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

Feb 11 2013

Cures Excitement May Wane While Senate Works

Jul 10 2015

Congressional ‘Cures’ Debate Shifts To FDA Funding

Apr 30 2015

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

Mar 03 2016

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

21<sup>st</sup> Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’

Nov 28 2016

The Evolution Of 21<sup>st</sup> Century Cures Legislation

Nov 30 2016

Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?

Nov 28 2016

Voucher Does Not Guarantee A Priority Review, FDA Says

Oct 06 2016

FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence

Nov 07 2016

Additional Topics

United States FDA Legislation Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window